Cargando…

Serum-Derived microRNAs as Prognostic Biomarkers in Osteosarcoma: A Meta-Analysis

Recent reports suggest that microRNAs (miRNAs) may serve as prognostic biomarkers in osteosarcoma. Due to osteosarcoma's early metastasis and poor prognosis, it is very important to find novel prognostic biomarkers for improving osteosarcoma's prognosis. Herein we propose a meta-analysis f...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Huan, Wang, Peng, Ye, Hua, Shi, Jianxiang, Dai, Liping, Wang, Xiao, Song, Chunhua, Zhang, Jianying, Li, Jitian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431663/
https://www.ncbi.nlm.nih.gov/pubmed/32849795
http://dx.doi.org/10.3389/fgene.2020.00789
_version_ 1783571630533902336
author Luo, Huan
Wang, Peng
Ye, Hua
Shi, Jianxiang
Dai, Liping
Wang, Xiao
Song, Chunhua
Zhang, Jianying
Li, Jitian
author_facet Luo, Huan
Wang, Peng
Ye, Hua
Shi, Jianxiang
Dai, Liping
Wang, Xiao
Song, Chunhua
Zhang, Jianying
Li, Jitian
author_sort Luo, Huan
collection PubMed
description Recent reports suggest that microRNAs (miRNAs) may serve as prognostic biomarkers in osteosarcoma. Due to osteosarcoma's early metastasis and poor prognosis, it is very important to find novel prognostic biomarkers for improving osteosarcoma's prognosis. Herein we propose a meta-analysis for serum miRNA's prognostic value in osteosarcoma. In this study, the literature available from PubMed, Web of Science, Embase, and Cochrane Library databases was reviewed. The pooled hazard ratios (HRs) with their 95% confidence intervals (CIs) were calculated to evaluate miRNAs prognostic values. A total of 20 studies investigating serum miRNAs were included in this meta-analysis; the initial terminal point of these reports included overall survival (OS), progression-free survival (PFS), disease-free survival (DFS), and recurrence-free survival (RFS). For prognostic meta-analyses, the pooled HR for terminal events of higher expression of miRNAs and lower expression of miRNAs were 5.68 (95% CI 4.73–6.82, P < 0.05) and 3.78 (95% CI 3.27–4.37, P < 0.05), respectively. Additionally, subgroup analyses were conducted based on the analysis methods applied and clinicopathological features reported. In the pooled analyses, the miRNA expression levels are associated with poor prognosis according to both univariate and multivariate analyses. Furthermore, serum miRNAs (miRNA-195, miRNA-27a, miRNA-191, miRNA-300, miRNA-326, miRNA-497, miRNA-95-3p, miRNA-223, miRNA-491-5p, miRNA-124, miRNA-101, miRNA-139-5p, miRNA-194) were associated with poor OS and found to be closely correlated with clinical stage and distant metastasis in osteosarcoma. The results illustrate that low or high expression of these specific miRNAs are both potentially useful as prognostic serum biomarkers in osteosarcoma, and miRNAs (miRNA-195, miRNA-27a, miRNA-191, miRNA-300, miRNA-326, miRNA-497, miRNA-95-3p, miRNA-223, miRNA-491-5p, miRNA-124, miRNA-101, miRNA-139-5p, miRNA-194) may indicate clinical stage and metastasis in this form of cancer.
format Online
Article
Text
id pubmed-7431663
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-74316632020-08-25 Serum-Derived microRNAs as Prognostic Biomarkers in Osteosarcoma: A Meta-Analysis Luo, Huan Wang, Peng Ye, Hua Shi, Jianxiang Dai, Liping Wang, Xiao Song, Chunhua Zhang, Jianying Li, Jitian Front Genet Genetics Recent reports suggest that microRNAs (miRNAs) may serve as prognostic biomarkers in osteosarcoma. Due to osteosarcoma's early metastasis and poor prognosis, it is very important to find novel prognostic biomarkers for improving osteosarcoma's prognosis. Herein we propose a meta-analysis for serum miRNA's prognostic value in osteosarcoma. In this study, the literature available from PubMed, Web of Science, Embase, and Cochrane Library databases was reviewed. The pooled hazard ratios (HRs) with their 95% confidence intervals (CIs) were calculated to evaluate miRNAs prognostic values. A total of 20 studies investigating serum miRNAs were included in this meta-analysis; the initial terminal point of these reports included overall survival (OS), progression-free survival (PFS), disease-free survival (DFS), and recurrence-free survival (RFS). For prognostic meta-analyses, the pooled HR for terminal events of higher expression of miRNAs and lower expression of miRNAs were 5.68 (95% CI 4.73–6.82, P < 0.05) and 3.78 (95% CI 3.27–4.37, P < 0.05), respectively. Additionally, subgroup analyses were conducted based on the analysis methods applied and clinicopathological features reported. In the pooled analyses, the miRNA expression levels are associated with poor prognosis according to both univariate and multivariate analyses. Furthermore, serum miRNAs (miRNA-195, miRNA-27a, miRNA-191, miRNA-300, miRNA-326, miRNA-497, miRNA-95-3p, miRNA-223, miRNA-491-5p, miRNA-124, miRNA-101, miRNA-139-5p, miRNA-194) were associated with poor OS and found to be closely correlated with clinical stage and distant metastasis in osteosarcoma. The results illustrate that low or high expression of these specific miRNAs are both potentially useful as prognostic serum biomarkers in osteosarcoma, and miRNAs (miRNA-195, miRNA-27a, miRNA-191, miRNA-300, miRNA-326, miRNA-497, miRNA-95-3p, miRNA-223, miRNA-491-5p, miRNA-124, miRNA-101, miRNA-139-5p, miRNA-194) may indicate clinical stage and metastasis in this form of cancer. Frontiers Media S.A. 2020-08-11 /pmc/articles/PMC7431663/ /pubmed/32849795 http://dx.doi.org/10.3389/fgene.2020.00789 Text en Copyright © 2020 Luo, Wang, Ye, Shi, Dai, Wang, Song, Zhang and Li. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Genetics
Luo, Huan
Wang, Peng
Ye, Hua
Shi, Jianxiang
Dai, Liping
Wang, Xiao
Song, Chunhua
Zhang, Jianying
Li, Jitian
Serum-Derived microRNAs as Prognostic Biomarkers in Osteosarcoma: A Meta-Analysis
title Serum-Derived microRNAs as Prognostic Biomarkers in Osteosarcoma: A Meta-Analysis
title_full Serum-Derived microRNAs as Prognostic Biomarkers in Osteosarcoma: A Meta-Analysis
title_fullStr Serum-Derived microRNAs as Prognostic Biomarkers in Osteosarcoma: A Meta-Analysis
title_full_unstemmed Serum-Derived microRNAs as Prognostic Biomarkers in Osteosarcoma: A Meta-Analysis
title_short Serum-Derived microRNAs as Prognostic Biomarkers in Osteosarcoma: A Meta-Analysis
title_sort serum-derived micrornas as prognostic biomarkers in osteosarcoma: a meta-analysis
topic Genetics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431663/
https://www.ncbi.nlm.nih.gov/pubmed/32849795
http://dx.doi.org/10.3389/fgene.2020.00789
work_keys_str_mv AT luohuan serumderivedmicrornasasprognosticbiomarkersinosteosarcomaametaanalysis
AT wangpeng serumderivedmicrornasasprognosticbiomarkersinosteosarcomaametaanalysis
AT yehua serumderivedmicrornasasprognosticbiomarkersinosteosarcomaametaanalysis
AT shijianxiang serumderivedmicrornasasprognosticbiomarkersinosteosarcomaametaanalysis
AT dailiping serumderivedmicrornasasprognosticbiomarkersinosteosarcomaametaanalysis
AT wangxiao serumderivedmicrornasasprognosticbiomarkersinosteosarcomaametaanalysis
AT songchunhua serumderivedmicrornasasprognosticbiomarkersinosteosarcomaametaanalysis
AT zhangjianying serumderivedmicrornasasprognosticbiomarkersinosteosarcomaametaanalysis
AT lijitian serumderivedmicrornasasprognosticbiomarkersinosteosarcomaametaanalysis